Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 1 and 2 (rs4244285, 681G>A) alleles in vitro.

Xenobiotica; the fate of foreign compounds in biological systems - 1 Oct 2024

Li Xue

Abstract excerpt

The drug-drug interaction (DDI) and CYP2C19 genetic variation can lead to a high blood concentration of voriconazole. CYP2C19 is a highly genetically polymorphic enzyme, and CYP2C19*2 is more frequent among Asians associated with reduced metabolism of drugs. Clinical study found that co-administration with omeprazole significantly increased voriconazole concentrations and there was an additive effect in CYP2C19*2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Cytochrome P-450 CYP2C19
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hep G2 Cells

Share to Omeprazole

Share to Voriconazole

Source

Identifiers

PMID: 39445918
DOI: 10.1080/00498254.2024.2421513

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 *1 and *2 (rs4244285, 681G>A) alleles in vitro.PMID 39445918Read ↗

Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.Semantic proximity Read ↗

<i><scp>CYP</scp>2C19</i> Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?Semantic proximity Read ↗

Evaluation of the relationship between polymorphisms in CYP2C19 and the single-dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study.Semantic proximity Read ↗

Impact of cytochrome P450 2C19 polymorphisms on the clinical efficacy and safety of voriconazole: an update systematic review and meta-analysis.Semantic proximity Read ↗

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practiceSemantic proximity Read ↗

CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugsSemantic proximity Read ↗

[CYP2C19 genetic polymorphism and monitoring voriconazole plasma concentrations in the treatment and prevention of invasive fungal disease for hematological patients].Semantic proximity Read ↗

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole TherapySemantic proximity Read ↗

A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis.Semantic proximity Read ↗

In vitro functional analysis of 24 novel CYP2C19 variants recently found in the Chinese Han population.Semantic proximity Read ↗

The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.